Trending Down-0.0053 (-1.3181%)
  • Bid / Lots
    0.3968/ 24
  • Ask / Lots
    0.4290/ 11
  • Open / Previous Close
    0.3950 / 0.4021
  • Day Range
    Low 0.3900
    High 0.4200
  • 52 Week Range
    Low 0.2054
    High 2.6800
  • Volume
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 0.4021
09:32 ET67440.41
09:34 ET52000.405
09:36 ET1000.405
09:41 ET5000.405
09:48 ET26000.405
09:50 ET2000.4051
09:54 ET7170.41
09:56 ET23000.4051
10:10 ET42000.41
10:12 ET7510.4038
10:15 ET23000.4005
10:17 ET81280.4006
10:24 ET5000.3951
10:26 ET1000.3951
10:28 ET49000.3952
10:42 ET29000.4
10:46 ET52970.3951
10:50 ET41600.3971
10:53 ET18580.395
11:04 ET219310.396
11:06 ET41080.396
11:08 ET171000.396
11:09 ET23000.3953
11:11 ET10000.3902
11:13 ET9000.3932
11:18 ET1310.3905
11:20 ET22790.397
11:29 ET2390.4005
11:33 ET1000.3967
12:00 ET1000.3968
12:23 ET1000.398649
12:39 ET2060.4
12:50 ET21120.400251
12:52 ET100000.3968
12:56 ET6690.3968
01:26 ET8000.3969
01:33 ET9100.3987
01:39 ET33050.3968
01:44 ET3930.3983
01:50 ET1500.3968
01:51 ET1250.4005
02:02 ET30000.398651
02:06 ET2500.4005
02:15 ET1100.3986
02:22 ET39620.4005
02:33 ET11750.396901
02:42 ET3000.3968
02:44 ET26000.405
02:56 ET5390.40145
03:07 ET10000.405
03:32 ET1000.3975
03:48 ET2000.396801
03:50 ET1250.3968
03:57 ET46980.3968
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesVLON
Vallon Pharmaceuticals Inc
United StatesATXI
Avenue Therapeutics Inc
United StatesQRON
Qrons Inc
United StatesGSTC
GlobeStar Therapeutics Corp
United StatesNBSE
NeuBase Therapeutics Inc
United StatesCAPS
Capstone Holding Corp
As of 2023-03-27

Company Information

Vallon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel abuse-deterrent medications for central nervous system (CNS) disorders. Its technology is designed to resist manipulation for snorting and provide barriers to injection. The Company’s lead investigational product candidate, Abuse-Deterrent Amphetamine Immediate-Release (ADAIR), an abuse-deterrent formulation of immediate release (IR) dextroamphetamine in development for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. ADAIR is designed to deter attempts to crush and snort and provides barriers to injection. In addition to ADAIR, the Company’s second product candidate, ADMIR, an abuse deterrent formulation of methylphenidate (Ritalin), for the treatment of ADHD.

Contact Information

Two Logan Square 100 N. 18Th Street, Suite 300PHILADELPHIA, PA, United States 19103


President, Chief Executive Officer, Director
David Baker
Chief Financial Officer
Leanne Kelly
Chief Medical Officer
Timothy Whitake
Independent Director
Richard Ammer
Independent Director
Meenu Chhabra Karson

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
Revenue (TTM)
Shares Outstanding
Dividend Yield
Annual Dividend Rate
Ex-Dividend Date
Pay Date
Book Value
P/E Ratio
Price/Sales (TTM)
Price/Cash Flow (TTM)
Operating Margin
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.